NEW YORK, April 20 (GenomeWeb News) - UBS today upgraded its assessment of Bruker BioSciences to "Buy" from "Neutral," two days after Bruker announced plans to purchase privately held Bruker Optics.
As GenomeWeb News reported on Tuesday, Bruker said it plans to pay $135 million for Bruker Optics, which makes molecular spectroscopy platforms, the companies said this week.
The acquisition will enable Bruker BioSciences to sell mass spectrometry, X-ray-analysis, and now molecular spectroscopy platforms for proteomics as well as chemical and materials analysis, Bruker said.